Table 4.
Network meta-analysis of FEV1% predicted.
| Control | 5.90 (−5.74, 17.54) |
6.98 (−5.12, 19.08) |
−1.22 (−13.32, 10.88) |
3.68 (−8.38, 15.73) |
2.84 (−8.52, 14.21) |
−4.46 (−15.59, 6.67) |
4.98 (−5.72, 15.67) |
0.52 (−9.94, 10.97) |
−0.81 (−11.52, 9.90) |
| −5.90 (−17.54, 5.74) |
AT | 1.08 (−15.71, 17.86) |
−7.12 (−23.91, 9.66) |
−2.22 (−18.98, 14.53) |
−3.06 (−19.32, 13.21) |
−10.36 (−26.47, 5.75) |
−0.92 (−16.73, 14.88) |
−5.38 (−21.03, 10.26) |
−6.71 (−22.53, 9.10) |
| −6.98 (−19.08, 5.12) |
−1.08 (−17.86, 15.71) |
Mx + Tx | −8.20 (−13.93 to −2.47)* |
−3.30 (−11.20, 4.60) |
−4.13 (−10.93, 2.67) |
−11.44 (−17.84 to −5.03)* |
−2.00 (−8.33, 4.33) |
−6.46 (−13.23, 0.31) |
−7.79 (−13.42 to −2.16)* |
| 1.22 (−10.88, 13.32) |
7.12 (−9.66, 23.91) |
8.20 (2.47, 13.93)* |
Mx | 4.90 (−3.00, 12.80) |
4.07 (−2.73, 10.87) |
−3.24 (−9.64, 3.17) |
6.20 (−0.13, 12.53) |
1.74 (−5.03, 8.51) |
0.41 (−5.22, 6.05) |
| −3.68 (−15.73, 8.38) |
2.22 (−14.53, 18.98) |
3.30 (−4.60, 11.20) |
−4.90 (−12.80, 3.00) |
EA + Tx | −0.83 (−7.55, 5.89) |
−8.14 (−14.46 to −1.81)* |
1.30 (−4.95, 7.55) |
−3.16 (−9.85, 3.53) |
−4.49 (−10.03, 1.05) |
| −2.84 (−14.21, 8.52) |
3.06 (−13.21, 19.32) |
4.13 (−2.67, 10.93) |
−4.07 (−10.87, 2.73) |
0.83 (−5.89, 7.55) |
WA + Tx | −7.31 (−12.21 to −2.40)* |
2.13 (−2.63, 6.90) |
−2.33 (−7.70, 3.04) |
−3.66 (−7.46, 0.15) |
| 4.46 (−6.67, 15.59) |
10.36 (−5.75, 26.47) |
11.44 (5.03, 17.84)* |
3.24 (−3.17. 9.64) |
8.14 (1.81, 14.46) |
7.31 (2.40, 12.21) |
WA | 9.44 (5.23, 13.65) |
4.98 (0.14, 9.81) |
3.65 (0.59, 6.70) |
| −4.98 (−15.67, 5.72) |
0.92 (−14.88, 16.73) |
2.00 (−4.33, 8.33) |
−6.20 (−12.53, 0.13) |
−1.30 (−7.55, 4.95) |
−2.13 (−6.90, 2.63) |
−9.44 (−13.65, 5.23)* |
A + Tx | −4.46 (−8.52 to −0.40)* |
−5.79 (−8.68 to −2.90)* |
| −0.52 (−10.97, 9.94) |
5.38 (−10.26, 21.03) |
6.46 (−0.31, 13.23) |
−1.74 (−8.51, 5.03) |
3.16 (−3.53, 9.85) |
2.33 (−3.04, 7.70) |
−4.98 (−9.81 to −0.14)* |
4.46 (0.40, 8.52) |
A | −1.33 (−5.09, 2.43) |
| 0.81 (−0.90, 11.52) |
6.71 (−9.10, 22.53) |
7.79 (2.16, 13.42) |
−0.41 (−6.05, 5.22) |
4.49 (−1.05, 10.03) |
3.66 (−0.15, 7.46) |
−3.65 (−6.70 to −0.59)* |
5.79 (2.90, 8.68) |
1.33 (−2.43, 5.09) |
Tx |
Estimates are presented as mean difference (MD) and 95% confidence interval. For the part in the upper right, the estimate of treatment effectiveness should be read as column-defining treatment compared to the row-defining treatment. An MD of more than 0 favors the treatment in the column in improving FEV1%. Blue grids indicate treatment in column better than treatment in row.
*
Statistically significant.